Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients

Indian Heart Journal

Volumn 67, Issue 1, 2015, Pages 23-26

  Shetty, Sadanand R ^a   Kumar, Soumitra ^b   Mathur, R P ^c   Sharma, Kamal H ^d   Jaiswal, Ashok D ^e  

^a D Y PATIL UNIVERSITY   (India)

^b VIVEKANANDA INSTITUTE OF MEDICAL SCIENCES   (India)

^c OSMANIA MEDICAL COLLEGE   (India)

^d B J MEDICAL COLLEGE   (India)

^e Zydus Tower Opposite Iscon Temple Satellite ^*  (India)

Author keywords

Diabetic dyslipidemia; PPAR; Saroglitazar; Triglycerides

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ATORVASTATIN; BROMOCRIPTINE; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SAROGLITAZAR; SIMVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL; ALPHA-ETHOXY-4-(2-(2-METHYL-5-(4-METHYLTHIO)PHENYL))-1H-PYRROL-1-YL)ETHOXY))BENZENEPROPANOIC ACID; GLUCOSE BLOOD LEVEL; LIPID; PHENYLPROPIONIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; DIABETES MELLITUS; DIABETIC DYSLIPIDEMIA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; INDIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; DYSLIPIDEMIAS; FOLLOW UP; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; LIPIDS; MALE; MIDDLE AGED; PHENYLPROPIONATES; PREVALENCE; PYRROLES; TREATMENT OUTCOME;

EID: 84925940306     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ihj.2015.02.007     Document Type: Article

References (19)

1. Global Status Report on Noncommunicable Diseases 2010 [Internet] 2015 World Health Organization Available from: http://www.who.int/nmh/publications/ncd-report-full-en.pdf
2. S. Yusuf, S. Hawken, S. Ounpuu On behalf of the INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
3. A. Mooradian Dyslipidemia in type 2 diabetes mellitus Nat Clin Pract Endocrinol Metab 5 2009 150 159
4. J.V. Selby, T. Peng, and A.J. Karter et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population Am J Manag Care 10 2004 Feb 163 170
5. K. Musunuru Atherogenic dyslipidemia: cardiovascular risk and dietary intervention Lipids 45 2010 907 914
6. R. Jani, V. Pai, and P. Jha et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg Compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI) Diabetes Technol Ther 16 2014 63 71
7. V. Pai, A. Paneerselvam, and S. Mukhopadhyay et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg Compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V) J Diabetes Sci Technol 8 2014 132 141
8. N. Stone, J. Robinson, and A. Lichtenstein et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines Circulation 129 2013 S1 S45
9. Cardiovascular disease and risk management Diabetes Care 38 2014 S49 S57
10. S. Joshi, R. Anjana, and M. Deepa et al. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study PLoS One 9 2014 e96808
11. 20th Annual Convention of the American Association of Physicians of Indian Origin Clinical Implications: Dyslipidemia in the Asian Indian Population June 29, 2002 [Internet] 2015 Available from: https://southasianheartcenter.org/docs/AAPImonograph.pdf
12. A. Jørgensen, R. Frikke-Schmidt, and B. Nordestgaard Loss-of-function mutations in APOC3 and risk of ischemic vascular disease J Vasc Surg 60 2014 1096
13. B. Nordestgaard, and A. Varbo Triglycerides and cardiovascular disease Lancet 384 2014 626 635
14. P.S. Jellinger, D.A. Smith, and A.E. Mehta et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary Endocr Pract 18 2012 Mar-Apr 269 293
15. A. Garber, M. Abrahamson, and J. Barzilay et al. American association of clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary Endocr Pract 19 2013 536 557
16. A. Catapano, J. Chapman, O. Wiklund, and M. Taskinen The new joint EAS/ESC guidelines for the management of dyslipidaemias Atherosclerosis 217 2011 1
17. Combination lipid therapy in type 2 diabetes N Engl J Med 363 2010 692 695
18. Accessdata.fda.gov. Drug Approval Package: Tricor (Fenofibrate) NDA #021203 [Internet] 2015 [cited 14 January 2015]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2001/21-203-Tricor.cfm
19. Drugs.com. Niacin Side Effects in Detail [Internet] 2015 [cited 14 January 2015]. Available from: Drugs.com http://www.drugs.com/sfx/niacin-side-effects.html